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Introduction: Adenocarcinomas, commonly present as a dominant lesion (DL) with addi-
tional nodules in the ipsilateral or contralateral lung. We sought to determine the fate
and management of the secondary nodules and to assess the risk of these nodules
using the Lung CT Screening Reporting and Data System (Lung-RADS) criteria and the
National Comprehensive Cancer Network (NCCN) Guidelines to determine if surveillance
is an appropriate strategy.
Methods: We retrospectively evaluated patients with lepidic growth pattern adenocarci-
noma and secondary nodules from 2000 to 2013. Risk assessment of the additional lesions
was completed with a simplified model of Lung-RADS and NCCN-Guidelines.
Results: Eighty-seven patients underwent resection of 87 DLs (Group 1) concurrently with
60 additional pulmonary nodules (Group 2), while 157 non-DLs were radiologically surveyed
over a median follow-up time of 3.2 years (Group 3). Malignancy was found in 29/60 (48%)
nodules in Group 2. Whereas, only 9/157 (6%) of the lesions in Group 3 enlarged, 4 of
which (2.5% of total) were found to be malignant, and then treated, while the remain-
ing nodules continued surveillance. After applying the Lung-RADS and NCCN simplified
models, nodules in Group 2 were at higher risk for lung cancer than those in Group 3.
Conclusion: In patients with lepidic growth pattern adenocarcinoma associated with mul-
tiple secondary nodules, surveillance of the remaining nodules, after resection of the DL,
is a reasonable strategy since these nodules exhibited a slow rate of growth and minimal
malignancy. In contrast, nodules resected from the ipsilateral lung at the time of the DL,
harbor malignancy in 48%. Risk assessment models may provide a useful and standardized
tool for clinical assessment of pulmonary nodules.
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INTRODUCTION
Advances in computed tomography (CT) as well as the increasing
number of lung cancer screening programs has led to an increase
in the detection of pulmonary nodules. The prevalence of mul-
tiple small lung nodules in the initial Early Lung Cancer Action
Program (ELCAP) study (1) was 23% and increased to 50% when
scans were performed with a thinner slice thickness (2). As a result,
many lung cancers present as a dominant lesion (DL) with 40–57%
having multiple secondary nodules particularly in the contralateral
lung (3–6). Moreover, invasive adenocarcinomas, particularly with
a lepidic component, have been associated with multiple nodules.
After resection of the DL, the management of the additional lung
nodules is quite varied and can include surgical resection, systemic
therapy, radiation, and surveillance (7). This creates a challenge in
clinical practice decision making since no standardized treatment
algorithm exists.
Several algorithms such as International Early Lung Cancer
Action Program (I-ELCAP) and National Comprehensive Cancer
Network (NCCN) have been used to assess the importance of nod-
ules identified during routine follow-up after identification or lung
cancer screening (8, 9). These systems take into consideration the
size of the different nodules, their morphology, and the changes
in size of the nodules but none have been utilized to assess the
risk of secondary nodules prior to and after cancer resection. The
aims of this study were (1) to determine the fate of the nodules
identified prior to and after resection of the dominant lung ade-
nocarcinoma; (2) to determine the management of the secondary
nodules; and (3) to retrospectively assess the risk of these nodules
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using the Lung CT Screening Reporting and Data System (Lung-
RADS) criteria (8) and the NCCN Guidelines (9) after lung cancer
surgery.
MATERIALS AND METHODS
We performed a retrospective chart and pathologic review from
2000 to 2013 of patients with lung adenocarcinoma with lep-
idic features presenting with additional lung nodules. Patients
were primarily identified from the Division of Thoracic Surgery
database and consequently confirmed as having “BAC” or adeno-
carcinoma with a “BAC” component in the Cellnetix Pathology
database. The Swedish Medical Center Institutional Review Board
approved the study protocol. Individual consent was waived due
to the retrospective nature of the study.
We initially identified 103 patients who presented with multi-
ple lung nodules. All patients underwent resection of the DL and
were evaluated as having “BAC” or adenocarcinoma with a “BAC”
component on pathology. The DL was defined as the one for which
the workup and surgery were performed. More specifically, the DL
was a new lesion clinically suspicious for malignancy, or a lesion
which on follow-up that had either enlarged in total size, developed
or increased its solid component, and/or was PET positive (SUV
>2.5) (10). Patients were defined as having multinodular disease
when the radiologist reported at least one lesion in addition to the
DL on the pre-operative imaging studies. We excluded 16 patients
after careful review of their charts: 4 with clinical stage IV at the
time of presentation, 4 having the DL with maximum diameter
>5 cm, 3 with clinical N1 or N2 disease, and 5 with mucinous
adenocarcinoma cell type. Thus, 87 patients were included in the
review and staged according to the 7th edition of the TNM staging
system (11).
Lung nodules in this study were defined as focal non-linear
opacity on chest imaging. They were characterized by size, loca-
tion, and morphology (solid, semi-solid, or non-solid). All non-
calcified nodules identified were included in the study but a
positive finding on the CT scan was a nodule measuring 6 mm
or more in the mean diameter (12). Nodules were placed into
one of three groups: Group 1 (G1) comprises the primary or DL;
Group 2 (G2) includes nodules resected concomitantly with the
DL or within 3 months of the DL resection; and Group 3 (G3)
includes any nodule that was identified on the pre operative scan
immediately prior to resection of the DL and was followed over
time. When the additional nodules were risk assessed, nodules in
G2 located in the same lobe as the DL were excluded since the
strategy of management for these nodules is less controversial.
We performed a multi-disciplinary review of the resected
secondary nodules to assess the histology using Martini and
Melamed criteria (13). Second primary or synchronous cancers
were decided if during evaluation of the specimen atypical ade-
nomatous hyperplasia (AAH) was identified and/or the secondary
lesion was associated with a lepidic pattern at the edge of the lesion.
Also, synchronous cancer was denoted if cell type and morphol-
ogy was different than the primary. In the case of contralateral
lesions, the mediastinal nodes were required to be uninvolved
with cancer in addition to the previous criteria. A metastatic
focus was denoted if morphology and cell type was similar to
the primary.
After resection of the DL, patients were followed-up on an out-
patient basis for surveillance and evaluation of recurrent disease
at 4 monthly intervals for the first 2 years, 6 monthly intervals for
the next 3 years, and then annually after 5 years. Patients would
undergo at least 1 annual CT scan with or without contrast
alternating with chest radiography, unless new findings dictated
further investigation. Co-existing nodules and any new nodules
were managed largely according to the I-ELCAP Algorithm and
Guidelines (12).
The overall growth of nodules was radiologically assessed by
the volume doubling time (VDT) measurement, which was calcu-
lated using the following equation based on the modified Schwartz
formula (14).
VDT =
[
Log 2× t][
Log (V2/V1)
]
t is the interval, measured by days, between the two CT scans
used for the assessment of nodule growth; while V 1 and V 2 are
the initial and final nodule volume, respectively. Nodule volume
(V )=pi/6(ab2), where a is the longest horizontal axis and b is the
maximum perpendicular diameter (15).
Each nodule was risk assessed by the following systems with the
baseline obtained on the CT scan immediately prior to surgery, at
each CT scan after surgery with the scan that identified a change
being recorded, and if a change in the nodule was identified if
any further testing such as PET, biopsy, or short interval CT was
performed. For nodules that enlarged we reported assessment at
baseline (Time 1), which means at the time of primary surgery
when the DL was resected, at the specific follow-up time when
lesions were found to be enlarged (Time 2) and then after addi-
tional diagnostic studies were performed due to suspicion of lung
cancer (Time 3). The term “diameter” in both models refers to the
mean of the longest diameter of the nodule and its perpendicular
diameter.
First, the “risk” of each nodule was evaluated by assessing the
additional nodules with a simplified model of either Lung-RADS
assessment categories (Table 1) (8). According to the Lung-RADS
system, we first applied the size thresholds to nodules that were
either identified at the pre-operative CT scan as at baseline CT
screening or found to be enlarged at the follow-up CT scan. We
then classified lesions into categories 2, 3, 4A, and 4B. When previ-
ous CT films or reports were available for the comparison, lesions
were classified using further descriptors by the same model based
on the presence of any nodule growth either overall or of the solid
component. Nodule growth was defined as an increase in size of
more than 1.5 mm of the mean diameter.
Second, the“risk”of each nodule was also assessed by the NCCN
Guidelines for lung cancer screening (Table 2) (9). Size thresholds
for solid, part-solid, and non-solid nodules were applied to each
lesion. In order to simplify the analysis as well as the interpretation
of results, lesions were grouped into A, B, and C NCCN cate-
gories. Category A includes nodules for which an annual repeat CT
screening was recommended while Category C includes those for
which a more intensive surveillance and aggressive work-up was
recommended. Finally, Category B is associated to an intermediate
degree of recommendation.
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Table 1 | Simplified models of lung-RADS assessment categories and NCCN Guidelines for lung cancer screening.
Model Size thresholds Category Descriptor Probability of
malignancy
Recommendation
Lung-rads – 0 Incomplete – –
– 1 Negative <1% Annual follow-up
Solid nodules: <6 mm 2 Benign appearance <1% Annual follow-up
Part-solid: <6 mm
Non-solid: <20 mm
Solid nodules: ≥6 to <8 mm or
new 4 to <6 mm
3 Probably benign 1–2% 6-month follow-up
Part-solid: ≥6 mm total diameter
(TD) with solid component (SC)
<6 mm or new <6 mm TD
Non-solid: ≥20 mm or new
Solid nodules: ≥8 to <15 mm or
new 6 to <8 mm or growing <8 mm
4A Suspicious 5–15% 3-month follow-up
Part-solid: ≥6 mm TD with SC ≥6 to
<8 mm or with a new or growing
<4 mm SC
Solid nodules: ≥15 mm or new or
growing and ≥8 mm
4B Suspicious >15% Consider tissue sampling
Part-solid: SC ≥8 mm or a new or
growing ≥4 mm SC
NCCN Guidelines Solid or part-solid nodules: <6 mm A – – Annual follow-up
Non-solid: ≤5 mm
Solid or part-solid nodules: 6–8 mm B – – 3 to 6-month follow-up
Non-solid: >5–10 mm
Solid or part-solid nodules: >8 mm C – – Consider tissue sampling
Non-solid: >10 mm
Italics font is used to differentiate morphology of the nodule.
Chi-square test was used to compare categorical variables.
Student’s t -test was used for single comparisons of continu-
ous variables and ANOVA test for multiple comparisons. A p
value <0.05 was considered significant. Statistical analyses were
performed using the SPSS 19.0 statistical software package (SPSS
Inc., Chicago, IL, USA).
RESULTS
A total of 87 patients with 304 nodules were included. Demo-
graphic characteristics of the patient cohort are demonstrated in
Table 2. Patients were predominantly women (84%), Caucasian
(84%), with a positive smoking history (78%) and had a mean
age at diagnosis of 69 years. The majority of patients had bilat-
eral disease at the time of presentation with a median number of
additional nodules per patient of 2 (IQR 1–4).
Group 1 includes the 87 DLs that were resected, while Group
2 includes 60 additional nodules that were resected in addi-
tion to the DL: 57 were concomitantly removed and 3 were
subsequently removed from the contralateral lung at a subse-
quent additional operation within 3 months of the initial DL
surgery. Finally, Group 3 includes 157 additional nodules that
were radiologically observed. The radiological features of the nod-
ules within three groups are showed in Table 3. Nodule size, the
prevalence of mixed morphology and PET avidity were higher
in Group 1 compared to Group 3, while the proportion of nod-
ules with non-solid or solid morphology was greater in the Group
3. Additionally, the VDT of nodules progressively increased from
Group 1 to Group 3. The majority of additional nodules that
were resected in Group 2 were located in the same lobe (65%) as
the DL. The majority of nodules in Group 3 were contralateral
(65%).
Dominant lesions were resected by lobectomy, segmentectomy,
and wedge resection in 55, 17, and 28% of cases, respectively. Also,
60 additional nodules were resected, including 57 ipsilateral nod-
ules concomitantly removed with the DL. Specifically, 36/57 (63%)
lesions were in the same lung tissue of the resected DL, while 21/57
(37%) lesions required additional procedure, mainly a wedge
resection and a segmentectomy in two cases. Three contralat-
eral nodules were resected by a wedge resection at a subsequent
operation 3 and 8 weeks after resection of the DL.
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Table 2 | Demographic features of 87 patients.
Characteristic No. (%)
Age year, mean (SD) 69 (10)
Gender
Male 14 (16)
Female 73 (84)
Ethnicity
Caucasian 73 (84)
Asian 7 (8)
Other 7 (8)
Smoking history
Positive 68 (78)
PY, median (IQR) 26 (2–40)
Negative 19 (22)
Positive history of cancer (any site) 40 (46)
Lung adenocarcinoma 4 (5)
Symptoms at diagnosis
Yes 21 (24)
No 66 (76)
Pulmonary function, median (IQR)
FEV1 as % of predicted 90 (79–104)
DLCO as % of predicted 77 (64–87)
ECOG performance status 0–1 86 (99)
ASA score, median (IQR) 3 (2–3)
No. of lesions per patients, median (IQR) 2 (1–4)
Laterality per patient
Unilateral disease 22 (25)
Bilateral disease 65 (75)
Pathologic TNM stage (7th Ed.)
IA 58 (67)
IB 20 (23)
IIA 5 (6)
IIIA 4 (5)
All resected DLs in Group 1 were malignant, mainly consisting
of well or moderately well differentiated IA (Table 4). In Group
2, 39 nodules were in the same lobe as the DL and resected, while
18 were in the remaining ipsilateral lobes and 3 in the contralat-
eral lung and they were also resected. Of the 39 nodules in the
same lobe, 19 (49%) were found to be malignant whereas 10/21
(48%) of the nodules in the other ipsilateral or contralateral lobes
were malignant. In Group 3, nodules were followed for a median
3.2 years (IQR 1.8–6.0). Of these, 9/157 (6%) nodules enlarged
(Table 5) and four of which (2.5% of total) were found to be malig-
nant. Three were resected via wedge resection and were found to
be malignant, all consistent with IA. One was treated with stereo-
tactic body radiation therapy. The remaining 153 lesions continue
to be monitored.
A representative case is included in Figures 1A–D. This
was a 71-year-old, female, patient presented in 2010 with RML
DL (Figure 1A) as well additional bilateral pulmonary nodules
(Figures 1B–D). DL was resected by open lobectomy while RUL
(Figure 1B) and RLL (Figure 1C) nodules were wedged out during
the same operation. At definitive pathology, these were all found
to be invasive adenocarcinoma. Additional small nodules in the
left lung (Figure 1D) were radiologically observed and they were
stable at 43 months of follow-up.
After excluding nodules in the same lobe as the DL, the remain-
ing nodules in G2 and all nodules in G3 were assessed by using
a simplified Lung-RADS assessment and a modified version of
the NCCN Guidelines (Table 6). In Group 2, the Lung-RADS
system, placed 15/21 (71%) of the nodules in Category 2, which
predicts a <1% probability of malignancy yet 4/15 nodules in
this category were malignant. Lung-RADS correctly predicted
the malignancy rate in Category 3, Category 4A, and Category
4B. Comparatively, “NCCN suggested malignancies” were found
in 0/9 nodules in Category A, 3/4 in Category B, and 7/8 in
Category C.
In Group 3, Lung-RADS assessed a Category 2 risk to 137/157
(87%) nodules and NCCN assessed a Category A risk to 113/157
(72%) based on the CT prior to surgical resection of the DL.
During surveillance, all but nine nodules remained stable and the
nodules that were stable were down graded to a low risk category in
each system. Risk assessment was performed and reported on the
nodules that enlarged at three specific intervals of time as define in
the methods (Table 6). After assessment at Time 2, the additional
studies included short interval CT scan (6), PET-scan (1), antibi-
otic therapy (1), and percutaneous CT-guided biopsy (1). Four of
seven lesions remained in the high risk category and they were all
found to be malignant. The remaining three nodules were stable
and then classified into low risk category.
DISCUSSION
The primary finding in this study is that nodules identified on pre
operative imaging and followed after resection of the early stage
dominant adenocarcinoma have a low rate of enlargement and
only 2.5% become malignant at 3.2 years of follow-up. However,
resected nodules found in the ipsilateral lobes separate from the
DL have a rate of malignancy 48%. Nodules in the ipsilateral tho-
rax, size, morphology, location, PET avidity, and shorter VDT are
more concerning for malignancy. In addition, risk assessment with
Lung-RADS or NCCN nodule guidelines offer reassurance of the
importance of select non-dominant nodules that may benefit from
treatment. Taken together, these data would support a strategy of
surveillance of existing nodules after resection of the dominant
adenocarcinoma.
The rate of malignancy in these secondary nodules in our series
is similar to a recent analysis by Stiles and colleagues (16) who
determined the fate of these nodules in a more diverse group of
patients that included both adenocarcinoma and squamous car-
cinoma. They also demonstrated that 39% of nodules resected
concomitantly with the DL will be malignant, but nodules sur-
veyed after resection have a 4.8% rate of malignancy. This suggests
that a reasonable surgical approach in the ipsilateral chest is to
resect the known nodules found in the other lobes and address the
contralateral nodules with surveillance. Supporting this hypothe-
sis is the fact that ipsilateral location of the additional nodules was
found to be an independent predictor of malignancy, compared
to contralateral location (16). Additionally, this strategy allows the
surgeon to make a definitive diagnosis of lesions suspicion for lung
cancer during the same chest operation. However, without more
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Table 3 | Radiological features of the 304 nodules stratified by groups.
Characteristic No. (%) pValue
Group 1 Group 2 Group 3
No. of nodules 87 (29) 60 (20) 157 (52)
Size of the nodules
Median diameter (IQR) (cm)a 2 (1.5–2.9) 0.9 (0.5–1.3) 0.5 (0.3–0.6) (1, 2)<0.0001
(1, 3)<0.0001
(2, 3)<0.0001
Mean diameter <0.6 cmb 1 (1) 19 (32) 113 (72) <0.0001
Mean diameter ≥0.6 cmb 86 (99) 41 (68) 44 (28)
Morphology
Non solid 12 (14) 17 (28) 57 (36) <0.0001
Part solid 70 (80) 14 (23) 9 (6)
Solid 5 (6) 29 (48) 91 (58)
PET avidity (SUV >2.5)c 33 (43) 4 (7) 2 (1) <0.0001
Location, regarding the DL
Same lobe – 39 (65) 7 (4) <0.0001
Different ipsilateral lobe – 18 (30) 48 (31)
Contralateral – 3 (5) 102 (65)
VDT in days, median (IQR) 546 (346–745) 813 (460–922) 1110 (655–1339) (1, 2) 0.790
(1, 3) 0.003
(2, 3) 0.096
aMedian size of the nodules refers to the maximum diameter.
bMean diameter is an average of length and width, according to the International Early Lung Cancer Action Program (I-ELCAP) protocol (16).
cPET-scan was available for 76 nodules in Group 1, 56 in Group 2, and 136 in Group 3.
Table 4 | Pathologic features of resected nodules within three groups.
Characteristic No. (%) pValue
Group 1 (n=87) Group 2 Group 3 (n=157)
(n=21)a (n=39)b
No. of resected nodules 87 (100) 21 (100) 39 (100) 3 (2) <0.0001
Benign histology 0 (0) 11 (52) 20 (51) – <0.0001
Malignant histology 87 (100) 10 (48) 19 (49) 3 (100)
AIS 16 (18) 3 (30) 7 (37) – –
MIA 19 (22) – – –
IA 52 (60) 7 (70) 10 (53) 3 (100)
Metastases – – 2 (11) –
Histologic grade
1 37 (43) 4 (40) 7 (37) 1 (33) –
2 41 (47) 4 (40) 5 (26) 2 (66)
3 9 (10) – 3 (16) –
4 – – – –
Unknown – 2 (20) 4 (21) –
AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; IA, invasive adenocarcinoma.
aOnly nodules located in a different ipsilateral lobe as the DL or contralaterally.
bOnly nodules located in the same lobe of the DL.
predictive power than surgeon judgment the deep-seated lesion
in a lobe separate from the DL in the ipsilateral chest remains a
surgical challenge.
These results also suggest that there is some judgment by the
surgeon during pre-operative evaluation and during surgery that
deems these nodules to be important enough to consider resection.
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Table 5 | Characteristics of the additional 157 nodules that were
radiologically observed.
Characteristics No. (%) pValue
Enlarged
lesions
Unchanged
lesions
No. of lesions 9 (6) 148 (94) –
Location
Same lobe – 7 (5) 0.965
Different ipsilateral lobe 3 (33) 45 (30)
Contralateral lung 6 (67) 96 (65)
Morphology
Non-solid – 57 (39) <0.0001
Part-solid 7 (78) 2 (1)
Solid 2 (22) 89 (60)
Malignant histology 4 (44) – –
IA 3 (75) – –
NSCLCa 1 (25) –
aNodule biopsy was performed by CT-guided FNA only.
FIGURE 1 | DL (A) was resected concomitantly with lesions in
(B,C) (final pathology= IA) while nodules in (D) were radiologically
observed.
The surgical decision making is easier if these are peripheral lesions
amenable to additional wedge resections in a patient with excel-
lent pulmonary function. The decisions are more difficult with
a deeply seated lesion, multiple nodules or when operating on a
patient with limited pulmonary reserves. For appropriate lesions
that we are concerned about, we consider a pre surgery naviga-
tional bronchoscopy or even transthoracic needle biopsy to help
plan surgery at the current time.
During surgical planning, our results suggest that assessment
of the non-dominant nodule(s) using the NCCN Guidelines may
provide additional information. When the lesion was graded a Cat-
egory B or C risk on the pre-operative scan 10/12 (83%) lesions
were found to be malignant. Whereas, the assessment of risk by
Lung-RADS at a single point in time does not seem to provide
additional discrimination because this system relies in changes
over time to determine the likelihood of malignancy. However, the
size of the lesion is the primary indicator in the NCCN Guidelines
(>6 mm) and in a larger series of patients may be prone to “error”
with small lesions.
The application of both of these models during follow-up of
the 157 observed nodules seems to be appropriate since the sce-
nario is akin to lung cancer screening for which these two tools
were developed. In this situation, both size of the lesion and an
increase in the size of the lesion are key factors, which ultimately
determine risk. For most surgeons, these two factors already enter
into the evaluation of an existing pulmonary nodule. However,
growth rate and PET avidity of the nodules have also been shown
to represent important predictors of malignancy (17, 18), while the
presence of a solid component generally correlate with an invasive
adenocarcinoma (19). The value of continued surveillance and
risk assessment after resection is emphasized by our data. Even
though a number of nodules were assessed in the higher risk cat-
egory, following the I-ELCAP algorithm for nodule management
allowed many nodules to be down graded in concern while several
persisted in importance.
Whether and how these two risk assessment tools can be inte-
grated into our practice remains an ongoing process of evaluation.
Surgeons have two needs: determining the risk of nodules while
planning a surgical intervention and surveillance of nodules. One
interpretation of our data may be that neither of these risk assess-
ment tools was better than surgeon judgment in surgical planning
but there remains a need to be able to more reliably predict
malignancy since two studies show that half of nodules resected
were benign. We believe that surveillance of nodules whether at
screening or in cancer surveillance is a process for which our
team has followed nodules using the I-ELCAP protocol for over
a decade and this experience cannot be underestimated. How-
ever, an additional simplified tool for all team members may
be useful and the ultimate benefit of these models during sur-
veillance is that they provide a standardized tool for the whole
thoracic oncology team (radiology, oncology, surgeon) to use
rather than relying on one physician’s individual assessment for
clinical assessment of the radiological findings. A prospective
study to test the applicability to a non-screened cohort may be
of use.
There are several limitations to our study. First, we retrospec-
tively applied the risk assessment models to not only a predomi-
nant non-screened population, but also where we knew the final
histology of the nodules. Further prospective study and analysis is
required to ascertain if this is valid. Second, there was no mandated
CT slice thickness protocol. Most of the patients had a standard
dose chest CT scan with or without contrast but the slice thickness
varied from 2.5 to 5 mm, which could alter the nodule counts and
assessment. However, this is how patients present in clinical prac-
tice. Third, the duration of follow-up is relatively short at a median
of 3.2 years. Even though we may consider solid nodules that are
stable past 2 years of surveillance indolent, according to the Fleis-
chner society (20), 42% of the nodules in our series undergoing
surveillance were non-solid or part-solid and require a different
management algorithm and a longer duration of follow-up (21).
Despite the clinical indolent nature showed by nodules in Group
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Table 6 | Nodules risk assessment by Lung-RADS and NCCN Guidelines.
Model Category Group 2 Group 3 Enlarged lesions
Time 1 Time 2 Time 3
No. of nodules 21a 157 9 9 7b
Lung-RADS 2 15 (71%) 137 (87%) 7 (78%) 0 3 (33%)
3 3 (14%) 13 (8%) 2 (22%) 0 0
4A 1 (5%) 4 (3%) 0 7 (78%) 3 (33%)
4B 2 (10%) 3 (2%) 0 2 (22%) 1 (11%)
NCCN-Guidelines A 9 (43%) 113 (72%) 3 (33%) 0 3 (33%)
B 4 (19%) 26 (17%) 3 (33%) 1 (11%) 0
C 8 (38%) 18 (11%) 3 (33%) 8 (89%) 4 (44%)
Time 1= at baseline CT scan, Time 2=when nodule was found to be enlarged, Time 3=when additional diagnostic study was performed due to suspicion of lung
cancer.
aOnly nodules located in a different ipsilateral lobe as the DL or contralaterally.
bThe remaining two lesions were still under radiological surveillance when the risk assessment was performed.
3, malignant histology should not be excluded since pathology is
unknown for most of them. However, 72% of these nodules mea-
sured <6 mm in mean diameter and major lung cancer screening
protocols would address to them a less intensive follow-up, by
annual or 6-month CT scan (8, 9, 12), being the estimated risk of
malignancy <1% (8).
In summary, surveillance of the remaining nodules after resec-
tion of the DL in patients with adenocarcinoma and a lepidic
component associated with additional nodules is a reasonable
strategy. These nodules exhibited a growth rate of only 6% and
malignancy rate 2.5% in the 157 lesions for which follow-up strat-
egy was undertaken. In contrast, nodules resected at the time of the
DL harbor malignancy in 48% of the 21 nodules that were located
in a different lobe from the DL. Application of Lung-RADS and
NCCN risk categories may provide additional information about
the importance of theses nodules particularly as a more standard-
ized tool for the clinical assessment of multiple lung nodules but
requires further study.
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